Beta Bionics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$193.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Beta Bionics's estimated annual revenue is currently $18.8M per year.(i)
  • Beta Bionics's estimated revenue per employee is $155,000
  • Beta Bionics's total funding is $193.5M.

Employee Data

  • Beta Bionics has 121 Employees.(i)
  • Beta Bionics grew their employee count by 66% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Our commitment is first and foremost to the type 1 diabetes (T1D) community. Beta Bionics is proud to be a Massachusetts public benefit corporation. We believe we are one of the first, if not the first medical device company to be doing business as a benefit corporation, and weᅢᄁ¬ツᆲ¬トᄁre fairly certain that Beta Bionics is the first company to do so in the diabetes space. We believe our status as a public benefit corporation is going to make all the difference in the way we do business and, ultimately, will result in a healthier and happier T1D community. Hereᅢᄁ¬ツᆲ¬トᄁs why: Traditional corporations have one master: returning money to shareholders. Thatᅢᄁ¬ツᆲ¬トᄁs no secret and its pretty well established. Beta Bionics is different because our master is you, your kid (our kids), or another loved one that is living with diabetes -- it says so right in our founding corporate documents and we mean it. In fact, we have a member of our board of directors whose sole job is to make sure we remember to consider our public benefit mission in every decision we make. Chances are that if you have ever been to a Friends for Life conference, you have met Jeff Hitchcock, the director of the non-profit Children with Diabetes. This is our public benefit mission: 1)To provide and to protect Beta Bionics' turnkey solutions for safe and effective autonomous glycemic control 2)To bring Beta Bionics' technology to as many people with T1D as possible in an expeditious and responsible manner 3)To continue to innovate and to offer the latest advances as expeditiously and responsibly as possible 4)To act in the best possible interest of the T1D community in connection with fulfilling the Beta Bionics' corporate functions. We know that if we pursue our public benefit mission, everybody wins. So far, our investors love our structure. If they don't, we don't want them as investors, it's as simple as that. We'd love to hear your thoughts about our model and public mission.

keywords:N/A

$193.5M

Total Funding

121

Number of Employees

$18.8M

Revenue (est)

66%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Beta Bionics News

2022-04-20 - Artificial Pancreas Market Size, Outlook And Forecast ...

... Bigfoot Biomedical, Johnson & Johnson, Tandem Diabetes Care, Pancreum, TypeZero Technologies, Beta Bionics, Medtronic Plc.

2022-04-19 - Artificial Pancreas Devices Systems Sales Market Share 2022 ...

Bigfoot Biomedical; Beta Bionics; Admetsys; Insulet; Tandem Diabetes Care; Defymed. Artificial Pancreas Devices Systems Sales Market Breakdown by Type:.

2022-04-17 - Pivotal Trial Results of the iLet® Bionic Pancreas To Be ...

Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™. Since its founding in 2015, its mission is to help...

2018-01-02 - Beta Bionics takes step toward $25M financing round W h i t e p a p e r Weighing the Costs:

Artificial pancreas startup Beta Bionics has secured the first slice of a planned $25 million financing round. The announcement of the round's first $2.5 million comes six months after midphase data positioned Beta Bionics to look forward to a pivotal trial of its diabetes device. Sponsored by ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A12112%N/A
#2
$18.8M12142%$137.6M
#3
$15.7M12195%$696.2M
#4
$18.2M1212%N/A
#5
N/A12215%N/A